NSRX AMEX
Nasus Pharma Ltd.
1W: +12.6%
1M: +4.0%
3M: +13.9%
YTD: -48.1%
1Y: -34.7%
$3.92
+0.10 (+2.75%)
Weekly Expected Move ±8.5%
$3
$4
$4
$4
$5
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$1M
+6.0% ▲
Net Income
-$2M
-45.8% ▼
EPS (Diluted)
$-0.17
-41.7% ▼
EBITDA
-$2M
-59.3% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin | — | — | — |
| R&D Expenses | $1M | $567K | $335K |
| SG&A Expenses | $926K | $580K | $743K |
| Operating Expenses | $2M | $1M | $1M |
| Operating Income | -$2M | -$1M | -$1M |
| Operating Margin | — | — | — |
| Interest Expense | $18K | $49K | $29K |
| Income Before Tax | -$2M | -$1M | -$2M |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$2M | -$1M | -$2M |
| Net Margin | — | — | — |
| EPS (Diluted) | $-0.19 | $-0.12 | $-0.17 |
| EBITDA | -$2M | -$956K | -$2M |
| Shares Outstanding | 9M | 9M | 9M |